Supplementary Table 1- Cell lines included in this study

Cell line	Primary *EGFR* mutation	EGFR TKI treatments	EGFR TKI resistance Mechanism
HCC4006	L747-E749 deletion, A750P	N/A	
HCC2279	E746-A750 deletion	N/A	
HCC2935	E746-T751 deletion, S752I	N/A	
H1975	L858R/T790M	N/A	*EGFR* T790M
H1650	E746-A750 deletion	N/A	
DFCI81	E746-A750 deletion	Patient underwent several erlotinib/chemotherapy treatments	*MET* amplification
PC9	E746-A750 deletion	N/A	
PC9 GR4		PC9 cells treated with increasing concentrations of gefitinib *in vitro*	*EGFR* T790M (1)
PC9 DR1		PC9 GR4 cells treated with increasing concentrations of dacomitinib *in vitro*	*EGFR* T790M amplification (1)
PC9 Pfr3		PC9 cells treated with 1 μM dacomitinib *in vitro*	IGF-1R activation (2)
PC9 WZR12		PC9 GR4 cells treated with increasing concentrations of WZ4002 *in vitro*	*MAPK1* amplification (3)
HCC827	E746-A750 deletion	N/A	
HCC827 GR6		Increasing concentrations of gefitinib *in vitro*	*MET* amplification (4)
HCC827 EPR		Increasing concentrations of erlotinib *in vitro* plus 1 μM MET inhibitor PHA 665,752	*EGFR* T790M (5)
HCC827 + HGF		N/A	Transduction of cells with HGF leading to HGF secretion

1. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010;29:2346-56.
2. Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013;73:834-43.
3. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012;2:934-47.
4. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43.

5. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489-98.